Prescription drugs and managed care: can 'free-market detente' hold?

The rapid rise in pharmaceutical benefits costs, often cited as a major contributor to the resurgence in health care cost growth, is beginning to strain the relationship between the pharmaceutical and the managed care industries in the United States. In interviews conducted in 1999, executives from...

Full description

Saved in:
Bibliographic Details
Published in:Health Affairs 2000-03, Vol.19 (2), p.63-77
Main Author: Moran, D W
Format: Article
Language:English
Subjects:
Administrative Personnel - psychology
Attitude of Health Personnel
Cost benefit analysis
Cost Control
Debates
Detente
Deterioration
Drug Costs - statistics & numerical data
Drug Costs - trends
Drug Industry - organization & administration
Drug Prescriptions - economics
Facility Regulation and Control - organization & administration
Federal regulation
Free markets
Health care
Health care expenditures
Health care policy
Health maintenance organizations
Health services
HMOs
Humans
Insurance Benefits - economics
Interinstitutional Relations
Interviews
Leadership
Managed care
Managed Care Programs - organization & administration
Marketing of Health Services - organization & administration
Markets
Medicare
Pharmaceutical industry
Pharmaceuticals
Politics
Prescription drugs
Private Sector - organization & administration
Public interest
Public policy
Quality of Health Care
Surveys and Questionnaires
Think tanks
United States
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rapid rise in pharmaceutical benefits costs, often cited as a major contributor to the resurgence in health care cost growth, is beginning to strain the relationship between the pharmaceutical and the managed care industries in the United States. In interviews conducted in 1999, executives from both industries maintained a continued preference for a market-based resolution of these tensions. There is evidence, however, that this private-sector détente may give way in the face of the rising business and political pressures that both industries face. Active leadership will be required to prevent deterioration of the prevailing political climate toward economic controls.
ISSN:0278-2715
1544-5208
DOI:10.1377/hlthaff.19.2.63